Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
CMS Final Pricing for Genomic Procedure Codes Leaves Lab, Industry Stakeholders Wanting More
Premium
After going through the gapfill process and releasing final pricing for six codes related to genomic sequencing procedures, the final pricing still has stakeholders worried.
GenomeWeb Top 40 Rises 3 Percent in November Amidst Mixed Broader Market
In comparison, the Dow Jones Industrial Average rose 8 percent and the Nasdaq rose 6 percent, but the Nasdaq Biotech Index was in negative territory, falling by less than 1 percent.
Jury Awards Guardant Health $292.5M in False Advertising Lawsuit Against Natera
The companies have both claimed that the other has engaged in false advertising related to Signatera and Reveal MRD assays.
Consortium Catalogs Complex Structural Variation in Human Genomes With Hybrid Long-Read Assembly
Premium
The Human Genome Structural Variation Consortium recently released a new variant database generated from 65 nearly complete human genomes with T2T status.
Oxford Nanopore Technologies, UK Biobank Partner to Build Large-Scale Epigenetic Database
The initiative plans to profile the epigenomes of 50,000 UK Biobank participants, most of them healthy individuals, using nanopore sequencing.